This publication is important because it provides a standardized clinical pathway for MASLD assessment and management, which will improve the identification and care of affected individuals.
MASLD: a disease in flux - Nature
Oct 2, 2024 · In the past 20 years, the prevalence of MASLD has been rising rapidly, along with the contribution of MASLD as a major cause of cirrhosis and hepatocellular carcinoma (HCC).
A new treatment and updated clinical practice guidelines for MASLD
Nov 11, 2024 · Clinical practice guidelines support a case-finding strategy for metabolic dysfunction-associated steatotic liver disease (MASLD) with liver fibrosis using a stepwise approach to assess …
Pathophysiology, noninvasive diagnostics and emerging personalized ...
Aug 5, 2025 · MASLD and MASH are not confined to liver pathology but represent systemic metabolic disorders with profound implications across multiple organ systems.
Metabolic dysfunction-associated steatotic liver disease in adults ...
Mar 6, 2025 · MASLD is estimated to affect more than one-third of adults worldwide. MASLD is closely associated with insulin resistance, obesity, gut microbial dysbiosis and genetic risk factors.
Advances in MASLD/NAFLD - Nature
Jun 30, 2023 · With its increasing prevalence rate, MASLD is becoming the most common indication for liver transplantation and the main underlying aetiology for the development of liver cancer.
Metabolic dysfunction-associated steatotic liver disease and ...
Jan 26, 2026 · This Review discusses the strengths and weaknesses of prevalent MASLD and MASH-HCC preclinical models, expanding the discussion to the latest advances in vivo (for example, …
Immunopathogenic mechanisms and immunoregulatory therapies in …
Jun 10, 2025 · In this review, we describe the emerging data regarding the immunological mechanisms of MASLD (Fig. 1) and summarize data regarding new concepts related to immunoregulation-based …
Data-driven cluster analysis identifies distinct types of metabolic ...
Dec 9, 2024 · In the present study, using unsupervised hard clustering, we identified two distinct endotypes of at-risk MASLD, namely, cardiometabolic MASLD and liver-specific MASLD.
The importance of patient engagement in the multimodal treatment of …
May 1, 2025 · In this review, we discuss challenges and opportunities to actively engage with people living with MASLD in a multimodal treatment framework as a healthcare provider.